Clarivate PLC (NYSE:CLVT) Receives Consensus Rating of “Reduce” from Analysts

Clarivate PLC (NYSE:CLVT) has received an average rating of “Reduce” from the seven research firms that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $2.88.

A number of research firms recently weighed in on CLVT. Wall Street Zen upgraded Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Barclays lowered their price objective on shares of Clarivate from $2.50 to $2.00 and set an “underweight” rating on the stock in a research note on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a research report on Wednesday, June 24th.

Clarivate News Roundup

Here are the key news stories impacting Clarivate this week:

• Positive Sentiment: Clarivate reported adjusted earnings of $0.19 per share, ahead of analyst estimates of approximately $0.17-$0.18 and up from $0.18 a year earlier. Clarivate PLC Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management reaffirmed its 2026 financial outlook and said its Value Creation Plan is improving execution, sharpening the company’s strategic focus and supporting efforts to accelerate organic growth. Clarivate is also advancing the previously announced divestiture of its Life Sciences & Healthcare segment to improve its financial profile. Clarivate Reports Second Quarter 2026 Results
• Positive Sentiment: The earnings call highlighted strategic shifts and expanded use of artificial intelligence, which could support product innovation and longer-term competitiveness if these initiatives translate into stronger growth. Clarivate Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Clarivate appointed longtime company executive Michael Easton as executive vice president and CFO, effective August 8. He succeeds Jonathan Collins, who is leaving to pursue another opportunity. Easton brings more than 25 years of financial and operational experience, providing continuity but adding a management transition. Clarivate Appoints Michael Easton as Chief Financial Officer
• Negative Sentiment: Quarterly revenue of $587.3 million fell 5.5% year over year and was slightly below the roughly $589.7 million consensus estimate. Clarivate also continues to report a negative net margin, underscoring pressure on profitability despite the adjusted EPS beat. Clarivate Quarterly Earnings Report

Clarivate Stock Performance

Shares of Clarivate stock opened at $2.15 on Thursday. The firm’s fifty day simple moving average is $2.29 and its 200-day simple moving average is $2.43. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -10.21 and a beta of 1.38. Clarivate has a 12 month low of $1.66 and a 12 month high of $4.77. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.84 and a quick ratio of 0.84.

Clarivate (NYSE:CLVT) last announced its earnings results on Wednesday, July 29th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $587.30 million during the quarter, compared to the consensus estimate of $589.73 million. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The business’s quarterly revenue was down 5.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.18 earnings per share. As a group, equities analysts forecast that Clarivate will post 0.65 earnings per share for the current year.

Institutional Investors Weigh In On Clarivate

Hedge funds and other institutional investors have recently made changes to their positions in the business. FIL Ltd boosted its stake in Clarivate by 2.3% in the 4th quarter. FIL Ltd now owns 25,266,152 shares of the company’s stock worth $84,389,000 after buying an additional 567,170 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Clarivate by 3.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,768,783 shares of the company’s stock worth $83,373,000 after acquiring an additional 696,903 shares during the period. Atairos Partners GP Inc. grew its holdings in Clarivate by 195.3% in the fourth quarter. Atairos Partners GP Inc. now owns 10,232,667 shares of the company’s stock valued at $34,177,000 after purchasing an additional 6,767,667 shares during the period. Invenomic Capital Management LP grew its stake in shares of Clarivate by 3.8% during the 4th quarter. Invenomic Capital Management LP now owns 9,029,414 shares of the company’s stock valued at $30,158,000 after buying an additional 326,369 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Clarivate by 9.3% in the 3rd quarter. Vanguard Group Inc. now owns 8,922,585 shares of the company’s stock valued at $34,173,000 after purchasing an additional 756,722 shares in the last quarter. Hedge funds and other institutional investors own 85.72% of the company’s stock.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.